Abstract
Many cellular processes in cancer are attributed to kinase signaling networks. V-akt murine thymoma viral oncogene homolog (AKT) plays a major role in the PI3K/AKT signaling pathways. AKT is activated by PI3K or phosphoinositide-dependent kinases (PDK) as well as growth factors, inflammation, and DNA damage. Signal transduction occurs through downstream effectors such as mTOR, glycogen synthase kinase 3 beta (GSK3β), or forkhead box protein O1 (FOXO1). The abnormal overexpression or activation of AKT has been observed in many cancers, including ovarian, lung, and pancreatic cancers, and is associated with increased cancer cell proliferation and survival. Therefore, targeting AKT could provide an important approach for cancer prevention and therapy. In this review, we discuss the rationale for targeting AKT and also provide details regarding synthetic and natural AKT-targeting compounds and their associated studies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1019-1031 |
| Number of pages | 13 |
| Journal | Cancer Research |
| Volume | 79 |
| Issue number | 6 |
| DOIs | |
| State | Published - 2019 |
Bibliographical note
Funding Information:This work was supported by grants from the NIH (CA187027, CA166011, CA196639), Key Program of Henan Province, China (grant no. 161100510300 to Z. Dong), the National Natural Science Foundation of China (NSFC81672767 to M.-H. Lee), and Henan Provincial Government, China.
Publisher Copyright:
© 2019 American Association for Cancer Research.
Keywords
- Animals
- Antineoplastic Agents/therapeutic use
- Humans
- Molecular Targeted Therapy
- Neoplasms/drug therapy
- Proto-Oncogene Proteins c-akt/antagonists & inhibitors
PubMed: MeSH publication types
- Review
- Research Support, Non-U.S. Gov't
- Journal Article
- Research Support, N.I.H., Extramural
